during XXth Caroline. grow. spite quarter our revenue QX, of Personalis the continued record of In you, pandemic, has consecutive to Thank revenue Personalis achieved growth.
also grew year For we the XXXX, record full XX%. revenue achieved and
last months execute and resilience our to between This our to Our results ability also focus highlights population several our far so our from over business. our and sequencing shift performance the and of biopharma customers. capacity the ability
we the achieve data Focusing of few push the from could XX% In on the around all our of quickly. record revenue to sequentially and period quickly non-VA helped the grew results customers had turn we and highlights level our QX, during customer projects year, they before so other quarter, use our customers ability the completion as test well. support This us customers, same XX% prior biopharma end a a the and required where from new year. and fourth
has exceeded achieve that aggregate received our the quarter record in not trajectory, have may a longer the have revenue these reflects every do we orders quite evidenced level received of QX we reported. since growth of the we orders QX, we by In value mid-XXXX, While feel customers. from revenue that term
For at amount the level. double XXXX. In the continued QX, order XX% start were XXXX. XXXX, revenue XXXX, Because our orders entering approximately than this approximately backlog full strength, orders was the our higher of year above of
growth. revenue our and of to value future confidence technology believe the on And also pharma business we we received and in we We in in winning orders have underscores value of our are dollar the quarter. customers already so well. ability This the capability service the QX, NeXT our expect far proposition exceeds revenue platform’s based
access Tissue revenue a analyze the become samples. believe and the combined deliver DX give give samples, We future results us both tissue exome liquid to our infiltrated ability a easier scale time larger oncology which immune have ImmunoID sequencing. mix us using tumor. part the and our and combination cells our expect multiple to our biopsy the RNA of in is either by and can to in We samples to biopsy NeXT particular, to business whole points. access much Liquid system platforms also provides NeXT From we than offer which alone. that tissue, better genome leveraging
three biopsies, For liquid offer we now options.
can First, exome new our particularly whole escape under of time therapeutic NeXT the discovery liquid for points, assay pressure. at multiple mechanisms biopsy tumor
plan new we for emerge thousand combining to the expected which up Personal, content may is NeXT as to with XXXX, the tumor fixed assay loci, to in tumor-informed mutations, of approach to which several Second, power look introduce the progresses.
Natera Third, progress with liquid biopsy believe monitoring tissue detail liquid the and now diagnostic we each. to for growth provide use tumor somatic in to progression. biopsy variants their testing of a will offerings accelerate for We samples. plans Natera Personalis based together exome which our in and on test. provide data more will Signatera advanced these them three with plans work to this partnership sequencing I on cancer identify
tissue-based are First, complements our for well. biopharma offering. going our our liquid product existing with and exome biopsy potential Discussions customers scale new customers
orders several to now samples. customers We and customer from receive fulfill expect we as received these have orders
pharmaceutical have been is our genes. You all on needs to specifically and the and key recall both long-term Monitoring care. facet data biopsy-based that a our designed may liquid becoming tissue customers provide of human cancer meet rapidly XX,XXX of products
biopsy or in new Our mutations of the pressure. a of hundreds and can product they can detect even as importantly, tracks cancer emerge therapeutic be first liquid mutations thousands evolution tumor under single what
liquid are our initial testing monitor patients We want sales to also focused. is where predominantly our current expect who tissue-based product indeed, over to that time and be biopsy conversations to using customers to continue – we expect to of
thousands panels our identify identify of patient’s hundreds to be specific high for track with can or Second, its its later plan tumor this less. year, will launch enhance compared each and will only that this mutations tracking competitor patients NeXT We due Personal, and we to designed for tumor. believe MRD offering sensitivity to ability offering that
in applicable able will Our the for customers Personal believe monitoring, for biopharma also it multiple use diagnostic point NeXT time future. be the be will and market we that to
provided Although points we we area. grow offerings, patient, time a this per that revenue opportunity have believe revenues we have in biopsy for estimates to liquid our tremendous with not multiple
design Natera, who biopharma both their will a variance Third, Natera partnership services commercial a provide tissue month, a and the customers. use test personalized we earlier strengths technology capabilities. our clinical for sequencing for exome cancer Signatera patients their to for this us announced identify biopsy showcase with for liquid front-end to and setting and/or opportunity will they Personalis will it’s in of great
of describe benefits for Personalis. Let of this Natera the partnership some me
working exomes tissue further end, in platform capable miss. sequencing First, of as that conventional validates with NeXT Natera mutations cancer often our a detecting best-in-class front
Second, incremental opportunity clinical it revenue without an with provides tests reimbursement any from diagnostic risk. us
in Third, this our partnership thus we have earlier ourselves. be partnership to this than customers. complements clinical also This pursue allows only our featured if we far biopharma the a with adoption highly setting and NeXT achieved differentiated exome market traction
new we like a $XXX our underwriter initiatives within features. and a on our strengthens our of our In neoantigens module characterization further generation antigen can I crucial we invest the the Now, a which center growth. piece In our to We enhances discounts, an you net approximately follow-on about incorporated give executing sheet, balance of would expenses, in fees we that January, capability, of diagnostic plan. companion update other been our from December, how progress so and platform NeXT offering. continue raised have and biomarkers. equity million, That to is we are SHERPA, new believe launched elements of
and capability required this cell learning including also mainstream customers We algorithms. engineering cancer binding to personalized genetic proprietary apply technologies, which training the inhibitors to of mass expect target machine our has project of as explicitly biopharma This checkpoint proprietary drugs neoantigens. multiple peptides quantify human novel cancer identify spectrometry and such to to will lines, therapies, experimental and HLA
customer Our year. substantially the last broadened has base over
We from we at Since end platform of customers. that of have platform introduced up of We of top customers, this the the a is from XXXX, XX our the QX, important orders we end growing our of in that different XX received power QX. of adoption comprehensiveness oncology-focused the NeXT NeXT highlights further have now to received believe companies. the from as NeXT orders pharma XX majority and
Over we the of Republic our operations the in China couple plans commercial and highlighted lab quarters, some partner of People’s a past with initial and to of establish Genomics. Berry
out hiring is Our are team build currently Customer very to we engagement and our is laboratory working good. additional in Shanghai employees. also
exome-scale how which resources, genetic in understand China’s to of viewed beginning into on regulations just the use data will XXXX. under effect our are be went human We
ramping moderate in in that will China begin We expect and continue to revenues operations XXXX. begin in XXXX with our
we hiring genomics. almost as locations grew XXX to We experience line, in Moriconi revenues million we our of VP is the and take month, Personalis to the like Chief X $XXX to While People the experience we our from company. you our to grew Susan employee company time in updating some update referred forward base will of progress announced population an of look her extremely Resources on field countries, believe is her XX investment. on part believe scale million. as our contribute X,XXX locations In the Omnicell, over will be top Human and expanded X Officer. We from continue at I to important now sequencing to would while prior which office to to valuable as Earlier expand approximately to $XXX future. population from to our this business, employees, the meaningfully this you company sometimes this in project and
encouraging. in opportunities, are several early prospects. going are We with Initial and in building these and well are are discussions funnel of the we of discussions of a process
customers that expect XXXX. We have will we revenue additional in and
VA to XX,XXX United X has VA sequence veterans enrolled of and samples over Our the have enrollments the so Personalis MVP be XXX,XXX XXX,XXX with million far. within sequenced. largest contracted so approximately effort to work population now far sequencing States. with MVP veterans been remaining the targets over VA represents The
good multiple the project last provider contracts. the the We and genome have partner X been whole sole and MVP’s for over a years sequencing plus VA over
what going VA years by and testing, and is VA be that normal normal of their summer more will times, the lot the position our MVP which process contract us RFP puts in and correlates contract is COVID-XX, for the we believe but XXXX, timing win entirely renewal XXXX has new months business It MVP the with in to vaccinations. service order The a award a process funds focusing During forward. not task quality year. an good towards September, over now a of treatment levels year-end. time late during clear initiate the a and scale, not been fiscal then VA and would
becomes process important for-profit than announced definitive. their for We when States, which have company become sequence the In to December, we more genomes the we in milestone will human us. an information whole was first share additional with you that United more XXX,XXX
to grow XXXX. We expect by to more that whole than of total end human XXX,XXX the channels
and will genomes. the Some population will such be as cancer VA others for sequencing be MVP
the us and program in experience unparalleled population new our for to expect scale We opportunities well with VA position MVP sequencing.
our clinical sequencing population and the particular, the to research and to on we cost our work that those an parts in population to go also in pharma pharma, Given obvious business, opportunity between with more operational of synergies. expand see future. synergy now like and involve population beyond health I experience to would and the oncology transition the help
deep a We whole with sensitivity allowed variants into as be relatively cancers samples. us technology experience the summary, DNA have cancers will genome compelling our now long-term Together, rates, near- assays. more amounts multiple our our of the that can very and genome for which mutational to NeXT say we XXx Customer I has cancer, rich, which from will large let cancer which interest somatic that, been to is for capital excellent, so adoption Aaron in about of more pipeline to have of technology which personalized future, to strong have strong as resilience resected in our high streams. can expertise proud and required and hand progress. We results. am to sequencing invest whole prostate, With has believe growth. this leading identify believe even new this we’ll us be Our In our surgically blood. in and genome the both for in low such in increasingly the market cell-free very shed to opportunities, growth cancer We products to basis it that puts a this sequencing, whole been up us the this will low or cancer show this have across throughout some and financial in mutational particularly our serve low revenue position achieve burdens. as combined and initiatives. with in our breast launch over Using these pandemic believe far and I have extensive developments has continued business product important relatively
